News Sentiment

GPCR sentiment intelligence

Structure Therapeutics Inc. American Depositary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 53.36 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-0.2% over one week, +24.3% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Negative

Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS

Market Reaction

Balanced read

55/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend inactive 24.3% over four weeks
Fair value 36.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 32
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 16
Stock Titan 8
simplywall.st 4
TradingView 4
TradingKey 4
Investing.com Canada 3
Quartr 3
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 35
Earnings 11
Analyst action 6
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-53 of 53
Investing.com Canada Direct company coverage

H.C. Wainwright cuts Structure Therapeutics stock price target to $70 By Investing.com

H.C. Wainwright has lowered its price target for Structure Therapeutics (GPCR) to $70 from $100, while maintaining a Buy rating. The adjustment reflects heightened competitive pressures in the market for GLP-1 treatments, prompting a reassessment of penetration assumptions. Despi

Tone
Negative 37/100
Event
Analyst action
Published
11 Jun 2026 11:10
Source
Investing.com Canada